Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. And recent changes in healthcare policies across APAC, such as China’s fast tracking approval of therapies for severe and rare diseases, have reignited interest in the APAC region as a strong market for oncology.
Optimise your digital assets with UX research
The healthcare industry is increasingly using digital channels to deliver information and services to its’ customers. But for these to be communicated effectively, in a way that increases brand loyalty, it’s critical that patients, HCPs, and any other stakeholders have a positive user experience. Conducting UX research can help ensure the products or services being delivered through various digital touch points are designed in a way that brings real value to the consumer and results in a positive brand experience.
Live from Singapore: Full speed ahead - Unlock the full potential of your brand tracking
You know that you need to conduct regular research to track the performance of your brand. But is your brand tracking delivering the insights your stakeholders need?
If you’re setting up a new brand tracker or you’ve already got one but you’re not sure it’s performing at its best, this webcast is for you.
Combination therapies in oncology: The benefits of integrated insights
In association with Pharmaceutical Executive
Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.